Mahdavi Seied Rabi, Rezaeyan Abolhasan, Nikoofar Alireza, Bakhshandeh Mohsen, Farahani Saeid, Cheraghi Susan
Radiation Biology Research Center; Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
J Cancer Res Ther. 2020 Apr-Jun;16(3):539-545. doi: 10.4103/jcrt.JCRT_891_16.
The purpose of this study was to assess and compare the incidence and severity of sensorineural hearing loss (SNHL) in head-and-neck patients undergoing radiotherapy (RT) and concurrent cisplatin-based chemoradiotherapy (CRT).
Pure tone audiometry (PTA) was performed at 0.25-12 kHz on 35 RT and 25 CRT patients after 12-month followed up. The hearing loss was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) criteria.
SNHL increased to 84% in patients who had received CRT, compared with 26% increasing in patients who had treated with RT. There was an increased risk of SNHL at all frequencies for ears received a cochlear mean dose >50 Gy in RT group, compared to those receiving cochlear mean dose >30 Gy in CRT group. SNHL was more severe at higher frequencies in both patient groups.
Characteristic of radiation-induced SNHL is different from CRT-induced SNHL, especially in threshold radiation dose and PTA frequency.
本研究旨在评估和比较接受放射治疗（RT）和基于顺铂的同步放化疗（CRT）的头颈患者感音神经性听力损失（SNHL）的发生率和严重程度。
对35例接受放疗和25例接受同步放化疗的患者在随访12个月后进行0.25 - 12kHz的纯音听力测定（PTA）。根据不良事件通用术语标准（CTCAE）标准评估听力损失。
接受同步放化疗的患者中SNHL增加至84%，而接受放疗的患者中这一比例增加至26%。与接受耳蜗平均剂量>30Gy的同步放化疗组相比，放疗组中接受耳蜗平均剂量>50Gy的耳朵在所有频率下发生SNHL的风险均增加。两组患者中高频段的SNHL更严重。
辐射诱导的SNHL的特征与同步放化疗诱导的SNHL不同，尤其是在阈值辐射剂量和PTA频率方面。
